ESSA Pharma (EPIX) News Today $1.83 +0.07 (+3.98%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIXNovember 18, 2024 | prnewswire.comESSA Pharma (NASDAQ:EPIX) Shares Cross Below 50-Day Moving Average - Here's What HappenedESSA Pharma (NASDAQ:EPIX) Stock Passes Below Fifty Day Moving Average - What's Next?November 14, 2024 | marketbeat.comPiper Sandler Downgrades ESSA Pharma (EPIX)November 6, 2024 | msn.comOppenheimer Downgrades ESSA Pharma (EPIX)November 6, 2024 | msn.comGrowth N. V. Biotech Sells 7,879,583 Shares of ESSA Pharma Inc. (NASDAQ:EPIX) StockNovember 6, 2024 | insidertrades.comESSA Pharma Downgraded to Hold Amid Masofaniten Trial Termination and Revised Financial OutlookNovember 4, 2024 | markets.businessinsider.comEssa Pharma downgraded to Perform from Outperform at OppenheimerNovember 4, 2024 | markets.businessinsider.comESSA Pharma (NASDAQ:EPIX) Stock Rating Lowered by Jefferies Financial GroupJefferies Financial Group downgraded ESSA Pharma from a "buy" rating to a "hold" rating in a report on Monday.November 4, 2024 | marketbeat.comESSA Pharma Faces Uncertainty After Discontinuing Masofaniten Programs, Receives Hold RatingNovember 3, 2024 | markets.businessinsider.comJones Trading Downgrades ESSA Pharma (EPIX)November 2, 2024 | msn.comEssa Pharma terminates Phase 2 study of masofaniten combo in mCRPCNovember 2, 2024 | markets.businessinsider.comEssa Pharma downgraded to Hold from Buy at JonesResearchNovember 1, 2024 | markets.businessinsider.comEssa Pharma downgraded to Hold from Buy at JefferiesNovember 1, 2024 | markets.businessinsider.comEssa Pharma Shares Drop After Lead Drug Candidate FailsNovember 1, 2024 | marketwatch.comCancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination TherapyNovember 1, 2024 | benzinga.comESSA Pharma tanks after terminating trial for its prostate cancer treatmentNovember 1, 2024 | msn.comESSA Pharma (NASDAQ:EPIX) Share Price Crosses Below Fifty Day Moving Average - Should You Sell?ESSA Pharma (NASDAQ:EPIX) Stock Crosses Below Fifty Day Moving Average - What's Next?November 1, 2024 | marketbeat.comESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate CancerOctober 31, 2024 | prnewswire.comESSA Pharma (NASDAQ:EPIX) Stock Passes Above Fifty Day Moving Average - What's Next?ESSA Pharma (NASDAQ:EPIX) Share Price Passes Above Fifty Day Moving Average - Here's What HappenedOctober 16, 2024 | marketbeat.comESSA Pharma (NASDAQ:EPIX) Stock Price Passes Above 50-Day Moving Average of $5.52ESSA Pharma (NASDAQ:EPIX) Stock Passes Above 50-Day Moving Average of $5.52September 27, 2024 | marketbeat.comESSA Pharma (NASDAQ:EPIX) Stock Price Crosses Above 50-Day Moving Average of $5.44ESSA Pharma (NASDAQ:EPIX) Shares Pass Above Fifty Day Moving Average of $5.44September 19, 2024 | marketbeat.comESSA Pharma shares poised for growth as PSA90 rates improve in mCRPC trialSeptember 18, 2024 | uk.investing.comESSA Pharma maintains Overweight rating from Piper SandlerSeptember 18, 2024 | uk.investing.comESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth PlansSeptember 17, 2024 | finance.yahoo.comBuy Rating Affirmed for ESSA Pharma on Strong Clinical Data and Promising Future ProspectsSeptember 15, 2024 | markets.businessinsider.comESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO CongressSeptember 13, 2024 | prnewswire.comESSA Pharma to Present at the 2024 Cantor Global Healthcare ConferenceSeptember 11, 2024 | prnewswire.comESSA Pharma Inc. (NASDAQ:EPIX) COO Peter Virsik Sells 2,082 SharesSeptember 4, 2024 | insidertrades.comPiper Sandler Remains a Buy on ESSA Pharma (EPIX)August 30, 2024 | markets.businessinsider.comESSA Pharma (NASDAQ:EPIX) Stock Price Crosses Below 50 Day Moving Average of $5.04ESSA Pharma (NASDAQ:EPIX) Shares Pass Below 50-Day Moving Average of $5.04August 22, 2024 | marketbeat.comESSA Pharma (NASDAQ:EPIX) Share Price Passes Below 50 Day Moving Average of $5.09ESSA Pharma (NASDAQ:EPIX) Stock Price Crosses Below 50 Day Moving Average of $5.09August 14, 2024 | marketbeat.comEPIX: Updated Masofaniten plus Enzalutamide Dose Escalation Data to be Presented at ESMO 2024…August 8, 2024 | msn.comESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024August 5, 2024 | prnewswire.comESSA Pharma to Present at the JonesHealthcare Seaside SummitJuly 8, 2024 | prnewswire.comESSA Pharma (NASDAQ:EPIX) Shares Cross Below 50 Day Moving Average of $5.83ESSA Pharma (NASDAQ:EPIX) Stock Crosses Below 50-Day Moving Average of $5.83July 4, 2024 | marketbeat.comESSA Pharma Inc. (NASDAQ:EPIX) Sees Large Decline in Short InterestESSA Pharma Inc. (NASDAQ:EPIX - Get Free Report) (TSE:EPI) was the recipient of a large decline in short interest in May. As of May 31st, there was short interest totalling 843,700 shares, a decline of 7.6% from the May 15th total of 913,100 shares. Based on an average daily trading volume, of 58,700 shares, the days-to-cover ratio is currently 14.4 days.June 19, 2024 | marketbeat.com2,298,662 Shares in ESSA Pharma Inc. (NASDAQ:EPIX) Purchased by RTW Investments LPRTW Investments LP purchased a new position in ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) (TSE:EPI) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,298,662 shares of the company'June 7, 2024 | marketbeat.comESSA Pharma to Present at the Jefferies Global Healthcare ConferenceMay 30, 2024 | prnewswire.comESSA Pharma (NASDAQ:EPIX) Share Price Passes Below Fifty Day Moving Average of $7.33ESSA Pharma (NASDAQ:EPIX) Stock Price Crosses Below 50 Day Moving Average of $7.33May 24, 2024 | marketbeat.comInsider Stock Buying Reaches US$709.0k On ESSA PharmaMay 21, 2024 | finance.yahoo.comOppenheimer Reiterates "Outperform" Rating for ESSA Pharma (NASDAQ:EPIX)Oppenheimer reissued an "outperform" rating and set a $17.00 target price on shares of ESSA Pharma in a report on Thursday.May 16, 2024 | marketbeat.comBuy Rating Endorsed for ESSA Pharma on Robust Pipeline and Market Expansion PotentialMay 14, 2024 | markets.businessinsider.comESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024May 14, 2024 | prnewswire.comShort Interest in ESSA Pharma Inc. (NASDAQ:EPIX) Drops By 13.5%ESSA Pharma Inc. (NASDAQ:EPIX - Get Free Report) (TSE:EPI) was the recipient of a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 802,800 shares, a drop of 13.5% from the March 15th total of 928,600 shares. Based on an average trading volume of 154,100 shares, the days-to-cover ratio is presently 5.2 days.April 14, 2024 | marketbeat.comESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 9, 2024 | finance.yahoo.comESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 9, 2024 | prnewswire.comESSA Pharma (NASDAQ:EPIX) Is In A Strong Position To Grow Its BusinessApril 8, 2024 | finance.yahoo.comEssa Pharma COO sells shares worth over $5,500April 7, 2024 | investing.comESSA Pharma Inc EPIXApril 5, 2024 | morningstar.comESSA Pharma Inc. (NASDAQ:EPIX) Short Interest UpdateESSA Pharma Inc. (NASDAQ:EPIX - Get Free Report) (TSE:EPI) was the recipient of a significant decline in short interest during the month of February. As of February 29th, there was short interest totalling 979,400 shares, a decline of 13.3% from the February 14th total of 1,130,000 shares. Based on an average daily volume of 154,800 shares, the days-to-cover ratio is presently 6.3 days. Approximately 4.8% of the shares of the stock are sold short.March 16, 2024 | marketbeat.com Get ESSA Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter. Email Address 9 hidden AI stocks set to thrive in Trump’s new era (Ad)AI ETFs are Booming, But These 9 AI Stocks are Better Plays By 2030, the AI industry is projected to be worth trillions of dollars (here’s how to tap into this new wealth) Get the Name of These AI Picks Now EPIX Media Mentions By Week EPIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EPIX News Sentiment▼0.000.49▲Average Medical News Sentiment EPIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EPIX Articles This Week▼11▲EPIX Articles Average Week Get ESSA Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Kodiak Sciences News Aclaris Therapeutics News COMPASS Pathways News iTeos Therapeutics News Sage Therapeutics News Voyager Therapeutics News ProQR Therapeutics News uniQure News C4 Therapeutics News Rezolute News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EPIX) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredA “Thank You Gift” From Pres. Trump - GeniusTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ESSA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ESSA Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
